Clinical Trials Browser

OTHER × Carcinoma in Situ × Erlotinib Hydrochloride × Clear all

NCT00402779 2020-04-21

Erlotinib Prevention of Oral Cancer (EPOC)

Phase 3 Completed

303 enrolled 11 charts

Carcinoma in Situ, Mouth Neoplasms